1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab

Background

Despite recent advances in treatment of locally advanced non-small cell lung cancer (NSCLC) most patients suffer from relapse following treatment with chemoradiotherapy and consolidative Durvalumab. To date, no treatment standards have yet been established in current guidelines. As well, there is a paucity of data regarding effectiveness of different treatment options in relapsed/refractory (r/r) NSCLC. Here, we present preliminary data on treatment and outcome of r/r NSCLC patients in a real word setting.

Methods

So far, in this analysis we assessed patients from 10 German lung cancer centers undergoing treatment for r/r NSCLC between 06/2017 and 05/2023. Primarily, overall survival (OS) and progression-free survival (PFS) was estimated in this cohort and compared to historical outcomes. In addition, both different treatment options and OS/PFS were compared between subgroups. Last follow up will be assessed by June 30, 2023.

Results

N = 122 patients were retrospectively evaluated. Median OS from initial lung cancer diagnosis was 25.8 months (20.6 – 30.9) for the entire patient cohort. Following diagnosis of r/r disease median OS and PFS was 11.7 months (9.2 – 14.2) and 6.4 months (5.2 – 7.6), respectively. In relation to all patients undergoing systemic therapy as first -line treatment (70.5%), choice of systemic agents varied, with checkpoint inhibitors (with or without chemotherapy, 34.9%) most commonly administered, followed by platinum- (30.2%) or single agent-based chemotherapy (27.9%) and targeted therapies (7.0%). Interestingly, patients treated with targeted therapy or checkpoint inhibitor-based therapy benefited in terms of overall survival compared with patients who received chemotherapy alone.

Conclusions

Patients suffering from r/r disease represent a distinct patient population showing a dismal prognosis. However, choice of first-line therapy might affect overall survival. Besides improving early detection of NSCLC recurrence prospective clinical trials are warranted to further guide treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

D.C.C. Christoph: Financial Interests, Other: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Merck Sharp Dohme, Novartis, Novocure, Pfizer, Roche, Sanofi, Takeda. M. Wiesweg: Financial Interests, Personal, Invited Speaker: Amgen, Roche, Takeda, GSK, AstraZeneca; Financial Interests, Personal, Advisory Board: GSK, Novartis, Pfizer, Roche, Janssen, Daiichi Sankyo; Financial Interests, Institutional, Local PI: Takeda; Financial Interests, Institutional, Funding: Bristol Myers Squibb. T.R. Overbeck: Financial Interests, Personal, Other: AstraZeneca. All other authors have declared no conflicts of interest.